ReviewJournal of neurology2006
Basic principles of intravenous immunoglobulin (IVIg) treatment.
Review in Journal of neurology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- Targeted Treatments for Myasthenia Gravis in Children and Adolescents.Paediatric drugs · 2024Review
- High-dose IgG suppresses local inflammation and facilitates functional recovery after olfactory system injury.Annals of clinical and translational neurology · 2022Article
- Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.Therapeutic advances in chronic disease · 2022Review
- Application of 3D bioprinting in the prevention and the therapy for human diseases.Signal transduction and targeted therapy · 2021Review
- Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.International immunopharmacology · 2020Review
- Multiomics analyses identified epigenetic modulation of the S100A gene family in Kawasaki disease and their significant involvement in neutrophil transendothelial migration.Clinical epigenetics · 2018Article
- Antibody therapies for the prevention and treatment of viral infections.NPJ vaccines · 2017Article
- Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.Clinical reviews in allergy & immunology · 2016Review
- Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients.Clinical and experimental immunology · 2014Article
- Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives.Journal of clinical immunology · 2014Review
- Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
- May early intervention with high dose intravenous immunoglobulin pose a potentially successful treatment for severe cases of tick-borne encephalitis?BMC infectious diseases · 2013Article
- Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury.Journal of neuroinflammation · 2012Article
- Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.Protein & cell · 2010Review
- Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.Drugs · 2010Review
- Atypical guillain-barré in the emergency department.The western journal of emergency medicine · 2010Article
- Optimization of immunoglobulin substitution therapy by a stochastic immune response model.PloS one · 2009Article
- Review
- New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.Therapeutic advances in neurological disorders · 2008Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The original rationale for the therapeutic application of immunoglobulins was prevention and treatment of infectious diseases. With the description of agammaglobulinemia, substitution therapy became the primary indication for the use of immunoglobulins. Limitations and side effects of the intramuscular administration of immunoglobulins led to the development of preparations for intravenous use (IVIg). In the early 1980s an immunomodulatory effect of IVIg was described. Since then, the efficacy of IVIg has been established in controlled trials for diseases like idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome, dermatomyositis, and many others. There is a large body of evidence that IVIg can modulate an immune reaction at the level of T cells, B cells, and macrophages, interferes with antibody production and degradation, modulates the complement cascade, and has effects on the cytokine network. However, the precise mechanism of action is not yet clear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.